The Deep Vein Thrombosis (DVT) drugs in development market research report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Deep Vein Thrombosis (DVT). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Deep Vein Thrombosis (DVT) by 12 companies/universities/institutes. The top development phase for Deep Vein Thrombosis (DVT) is preclinical with nine drugs in that stage. The Deep Vein Thrombosis (DVT) pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Deep Vein Thrombosis (DVT) pipeline products market are: Glycan Therapeutics, CarboMimetics and Taho Pharmaceuticals.
The key targets in the Deep Vein Thrombosis (DVT) pipeline products market include Coagulation Factor X, Antithrombin III, and Alpha 2 Antiplasmin.
The key mechanisms of action in the Deep Vein Thrombosis (DVT) pipeline product include Coagulation Factor X Inhibitor with eight drugs in Phase I. The Deep Vein Thrombosis (DVT) pipeline products include four routes of administration with the top ROA being Oral and four key molecule types in the Deep Vein Thrombosis (DVT) pipeline products market including Polysaccharide, and Small Molecule.
Deep Vein Thrombosis (DVT) overview
Deep vein thrombosis (DVT) is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema), and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease, and heart failure. Treatment includes thrombolytics and anticoagulants.
For a complete picture of Deep Vein Thrombosis (DVT)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
